MedTrace Logo

Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure

NCT01411735 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2017-11-06

No results posted yet for this study

Summary

BACKGROUND: Exercise intolerance is the primary symptom in older patients with heart failure and preserved ejection fraction (HFPEF), however little is known regarding its mechanisms and therapy.

METHODS: 71 elderly stable, compensated HFPEF patients (age 70+1 years; 80% women) with controlled blood pressure were randomized into a 12 month follow-up (FU) double-blind trial of enalapril 20 mg per day (E) vs. placebo (P). Assessments included: peak exercise oxygen consumption (VO2); six-minute walk test; Minnesota Living with HF Questionnaire (MLHF); MRI; Doppler-echocardiography; and vascular ultrasound.

Conditions

Interventions

DRUG

Enalapril

2.5mg titrated up to 10mg twice daily

DRUG

placebo

2.5mg titrated up to 10mg twice daily.

Sponsors & Collaborators

  • Wake Forest University

    lead OTHER

Principal Investigators

  • Dalane W Kitzman, MD · Professor of Medicine-Cardiology Section

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-07-31
Primary Completion
2004-06-30
Completion
2008-07-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01411735 on ClinicalTrials.gov